Rallybio Receives $12.5 Million Equity Milestone Payment from Recursion for Advancement of REV102 Program

– Milestone Payment Triggered by Initiation of Additional Preclinical Studies for REV102, a Potential First-in-Class Oral ENPP1 Inhibitor for Hypophosphatasia – – Extends Cash Runway through 2027 – NEW HAVEN, Conn. --(BUSINESS WIRE)--Sep. 3, 2025-- Rallybio Corporation (Nasdaq: RLYB), a